TG4010: A therapeutic vaccine against MUC1 expressing tumors.
Fiche publication
Date publication
août 2012
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIMACHER Jean-Marc
Tous les auteurs :
Limacher JM, Quoix E
Lien Pubmed
Résumé
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.
Référence
Oncoimmunology. 2012 Aug 1;1(5):791-792.